AU8624791A - Compounds - Google Patents

Compounds

Info

Publication number
AU8624791A
AU8624791A AU86247/91A AU8624791A AU8624791A AU 8624791 A AU8624791 A AU 8624791A AU 86247/91 A AU86247/91 A AU 86247/91A AU 8624791 A AU8624791 A AU 8624791A AU 8624791 A AU8624791 A AU 8624791A
Authority
AU
Australia
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU86247/91A
Inventor
David Gwynn Cooper
Deirdre Mary Bernadette Hickey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of AU8624791A publication Critical patent/AU8624791A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU86247/91A 1990-09-11 1991-09-10 Compounds Abandoned AU8624791A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9019841 1990-09-11
GB909019841A GB9019841D0 (en) 1990-09-11 1990-09-11 Compounds

Publications (1)

Publication Number Publication Date
AU8624791A true AU8624791A (en) 1992-03-30

Family

ID=10682016

Family Applications (1)

Application Number Title Priority Date Filing Date
AU86247/91A Abandoned AU8624791A (en) 1990-09-11 1991-09-10 Compounds

Country Status (5)

Country Link
EP (1) EP0548227A1 (en)
JP (1) JPH06500791A (en)
AU (1) AU8624791A (en)
GB (1) GB9019841D0 (en)
WO (1) WO1992004334A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2344309A1 (en) * 1998-09-17 2000-03-23 Scott A. Biller Method for treating diabetes employing an ap2 inhibitor and combination
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
EP1151092B1 (en) * 1999-02-12 2008-12-31 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions with afabp antisens nucleic acids
US7390824B1 (en) 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination
JP2005530800A (en) * 2002-05-15 2005-10-13 スミスクライン・ビーチャム・コーポレイション Benzoxazine and benzoxazinone substituted triazoles
CA2895392A1 (en) 2012-12-28 2014-07-03 The Board Of Trustees Of The University Of Arkansas Indole compounds for use in treating inflammation and cancer
SG11201508054UA (en) 2013-04-19 2015-11-27 Univ Arkansas Combretastatin analogs
WO2015153635A1 (en) * 2014-03-31 2015-10-08 Board Of Trustees Of The University Of Arkansas Disubstituted triazole analogs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1206403A (en) * 1966-12-15 1970-09-23 Wyeth John & Brother Ltd Oxazoles
FR2082166A5 (en) * 1970-03-05 1971-12-10 Aries Robert Salicyclic acid - substd oxazolyl alkanoates - analgesics, antipyretic antiinflammatories, antirheumatics
FR2104651A1 (en) * 1970-04-27 1972-04-21 Aries Robert Pyridylmethoxycarbonylalkyl thiazoles and oxazoles - - analgesics, tranquillisers, antipyretics, antiinflammatories, and a
US3948932A (en) * 1973-05-29 1976-04-06 Miles Laboratories, Inc. Phenyl- and (substituted)-phenyl-1,2,3-triazole-alkanoic and -alkenoic acids

Also Published As

Publication number Publication date
EP0548227A1 (en) 1993-06-30
JPH06500791A (en) 1994-01-27
GB9019841D0 (en) 1990-10-24
WO1992004334A1 (en) 1992-03-19

Similar Documents

Publication Publication Date Title
AU639126B2 (en) Oxorapamycin
AU7971691A (en) Diaminopyrimidine compounds
AU8791591A (en) Tnf-muteins
AU8375591A (en) Azacyclic compounds
AU7846991A (en) Aminobenzodiazepines
AU3803593A (en) Compounds
AU7867491A (en) Compounds
AU7956191A (en) Transportsystem
AU7804691A (en) N-pyridinesulfonyl-N-pyrimidinyl-or-triazinylureas
AU9030991A (en) Improved capacitor-sensor
AU8764191A (en) Ibuprofen-antihistamine combinations
AU1975092A (en) Compounds
AU7726391A (en) Slitterscorer
AU8079591A (en) Bisheterocyclic compound
AU5583190A (en) Compounds
AU2402792A (en) Alkanamidoammonium compound
AU6531090A (en) Swagable fitting
AU8624791A (en) Compounds
AU7566691A (en) Compostor
AU8740291A (en) 3d-spectacles
AU7587991A (en) Electrodermatome
AU7709991A (en) Phenoxyphenylsulphonyl compounds
AU8984191A (en) Thiadiazinones
AU5922994A (en) Oxazinobenzazole compounds
AU8516291A (en) Instant photograph-postcard